Avita Medical (NASDAQ:RCEL – Get Free Report) and Artivion (NYSE:AORT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Earnings and Valuation
This table compares Avita Medical and Artivion”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avita Medical | $71.61 million | 6.84 | -$48.59 million | ($1.18) | -13.20 |
| Artivion | $441.33 million | 2.12 | $9.77 million | ($0.36) | -53.25 |
Artivion has higher revenue and earnings than Avita Medical. Artivion is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Avita Medical has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Avita Medical and Artivion, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
| Artivion | 1 | 0 | 6 | 0 | 2.71 |
Avita Medical presently has a consensus price target of $16.60, suggesting a potential upside of 6.55%. Artivion has a consensus price target of $39.00, suggesting a potential upside of 103.44%. Given Artivion’s stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than Avita Medical.
Profitability
This table compares Avita Medical and Artivion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avita Medical | -42.65% | N/A | -71.34% |
| Artivion | -3.65% | 5.12% | 2.36% |
Insider and Institutional Ownership
27.7% of Avita Medical shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Artivion beats Avita Medical on 11 of the 14 factors compared between the two stocks.
About Avita Medical
AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.
About Artivion
Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.
Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.
